Journal article
Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis
Pharmacoepidemiology and drug safety, v 33(5), 5803
May 2024
PMID: 38685851
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
PurposeTo facilitate claims-based research on populations with juvenile idiopathic arthritis (JIA), we sought to validate an algorithm of new medication use as a proxy for worsening JIA disease activity.MethodsUsing electronic health record data from three pediatric centers, we defined new JIA medication use as (re)initiation of disease-modifying antirheumatic drugs or glucocorticoids (oral or intra-articular). Data were collected from 201 randomly selected subjects with (101) or without (100) new medication use. We assessed the positive predictive value (PPV) and negative predictive value (NPV) based on a reference standard of documented worsening of JIA disease activity. The algorithm was refined to optimize test characteristics.ResultsOverall, the medication-based algorithm had suboptimal performance in representing worsening JIA disease activity (PPV 69.3%, NPV 77.1%). However, algorithm performance improved for definitions specifying longer times after JIA diagnosis (>= 1-year post-diagnosis: PPV 82.9%, NPV 80.0%) or after initiation of prior JIA treatment (>= 1-year post-treatment: PPV 89.7%, NPV 80.0%).ConclusionAn algorithm for new JIA medication use appears to be a reasonable proxy for worsening JIA disease activity, particularly when specifying new use >= 1 year since initiating a prior JIA medication. This algorithm will be valuable for conducting research on JIA populations within administrative claims databases.
Metrics
1 Record Views
Details
- Title
- Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis
- Creators
- Kyoko Saito - Brown UniversityAvinash Gabbeta - St. Christopher's Hospital for ChildrenEvan Mulvihill - Nemours Childrens Hosp, Wilmington, DE USALina Al-Jaberi - Arkansas Children's HospitalTimothy Beukelman - Childhood Arthrit & Rheumatol Res Alliance, Washington, DC USAJames D. Lewis - University of PennsylvaniaCarlos D. Rose - Nemours Childrens Hosp, Wilmington, DE USABrian L. Strom - Rutgers, The State University of New JerseyDaniel B. Horton - Rutgers, The State University of New Jersey
- Publication Details
- Pharmacoepidemiology and drug safety, v 33(5), 5803
- Publisher
- Wiley
- Number of pages
- 11
- Grant note
- National Institute of Arthritis and Musculoskeletal and Skin Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) UL1TR003017 / National Center for Advancing Translational Sciences; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001209497800001
- Scopus ID
- 2-s2.0-85191824009
- Other Identifier
- 991022202105204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Pharmacology & Pharmacy
- Public, Environmental & Occupational Health